Otsuka Pharmaceutical

Total: $62.7 million

Top drug
Abilify: $62.4 million
Watch the TV commercial here >>

Japanese drugmaker Otsuka puts all of its advertising eggs into one product basket, and to good effect. Its atypical antipsychotic Abilify is well-recognized and a blockbuster. The drug is Otsuka's top product and brought in $4.2 billion last year, but it loses exclusivity in 2015. The company recently won FDA approval for a long-acting, once-per-month injectable version of the drug, but it's searching around for products to fill in behind Abilify. The drugmaker may have something new to advertise next year. It recently made an $886 million offer for Astex Pharmaceuticals ($ASTX), which specializes in cancer drugs. The California-based company developed a leukemia drug--Dacogen, marketed by Eisai and Johnson & Johnson's ($JNJ) Janssen unit--but its pipeline is what provides the greatest potential upside.

Otsuka Pharmaceutical
Read more on

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.